Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The analysis is based on results from the STEP 1 trial, published in 2021 in the New England Journal of Medicine , which showed the 2.4 mg dosage of semaglutide approved by the FDA for the treatment of obesity reduced body weight by an average of 14.9% along with reductions in several cardiovascular risk factors such as blood pressure and lipids
JAMA Health Forum 6 , e245015 (2025)
Liver Metabolism and Hepatic Signaling Research Retatrutide is also widely used in research involving hepatic metabolism and liver-associated signaling pathways
Your stomach naturally produces a protein that helps protect and repair the GI lining
Targeted microrna profiling reveals that exendin-4 modulates the expression of several MicroRNAs to reduce steatosis in HepG2 cells
Expanding Pipeline: Lilly's ongoing research with retatrutide suggests a strategy to maintain leadership in the incretin space
